Globus Medical Q2 2023 Earnings Report

Globus Medical EPS Results

• Actual EPS: $0.63
• Consensus EPS: $0.60
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: $0.56

Globus Medical Revenue Results

• Actual Revenue: $291.62 million
• Expected Revenue: $279.54 million
• Beat/Miss: Beat by +$12.08 million
• YoY Revenue Growth: +10.60%

Globus Medical Announcement Details

• Quarter: Q2 2023
• Date: 8/3/2023
• Time: After Market Closes

Globus Medical (NYSE:GMED), a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.